THANK YOU FOR SUBSCRIBING
Over the years, Cardialysis has set several milestones for itself and the cardiovascular domain. The BENESTENT study completed in 1994 revolutionized the use of coronary stents in catheterization laboratories. To date, this study remains one of the most cited papers in cardiovascular research. In 2010, the company reported the sponsor-driven RESOLUTE All Comers trial (2010, Medtronic) which is still used as a methodological reference for pivotal or post-marketing coronary stent trials. This study compared two drug-eluting stent platforms in an unrestricted coronary artery disease population using a non-inferiority trial design. Recently, Cardialysis has contributed to the sponsor-driven GALILEO trial (Bayer), randomizing the use of an anticoagulant versus an antiplatelet strategy after transcatheter aortic valve implantation in patients without other indication for anticoagulation. Contrary to the investigator’s hypothesis, GALILEO showed that anticoagulation was detrimental, highlighting the importance of randomized trials. These three studies were published in the New England Journal of Medicine.![]()
Our research expertise is linked to the medical leadership at the Erasmus University Medical Center for Core Lab activities and trial design as well as to partnerships with leading investigators worldwide
Share this Article:
Tweet
|
Company
Cardialysis
Headquarters
Rotterdam, The Netherlands
Management
Dr. Ernest Spitzer, Medical Director
Description
Cardialysis conducts clinical trials to investigate pharmaceutical and device therapies used in coronary heart disease or structural heart disease, where interventional device therapies are offered in hospital catheterization laboratories. The company has emerged as the epicenter of cardiovascular innovation, connecting sponsors and investigational sites in sponsor-driven studies, and linking grant-givers, steering committees, and investigational sites in investigator-initiated studies. Besides expanding its footprint in heart failure trials, the company is striving to offer its services at a lower cost to counter the COVID-19 effect while exploring new ways to improve innovation outcomes in multi-CRO projects